Klaria Pharma Holding Stock Cash Flow From Operations
KLAR Stock | SEK 0.36 0.02 5.26% |
Klaria Pharma Holding fundamentals help investors to digest information that contributes to Klaria Pharma's financial success or failures. It also enables traders to predict the movement of Klaria Stock. The fundamental analysis module provides a way to measure Klaria Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Klaria Pharma stock.
Klaria |
Klaria Pharma Holding Company Cash Flow From Operations Analysis
Klaria Pharma's Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Klaria Pharma Cash Flow From Operations | (24.8 M) |
Most of Klaria Pharma's fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Klaria Pharma Holding is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
Competition |
In accordance with the recently published financial statements, Klaria Pharma Holding has (24.8 Million) in Cash Flow From Operations. This is 104.7% lower than that of the Healthcare sector and 106.73% lower than that of the Drug Manufacturers - Specialty & Generic industry. The cash flow from operations for all Sweden stocks is 102.55% higher than that of the company.
Klaria Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Klaria Pharma's direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Klaria Pharma could also be used in its relative valuation, which is a method of valuing Klaria Pharma by comparing valuation metrics of similar companies.Klaria Pharma is currently under evaluation in cash flow from operations category among related companies.
Klaria Fundamentals
Return On Equity | -0.88 | |||
Return On Asset | -0.29 | |||
Operating Margin | (9.48) % | |||
Current Valuation | 88.14 M | |||
Shares Outstanding | 63.1 M | |||
Shares Owned By Insiders | 10.73 % | |||
Shares Owned By Institutions | 9.75 % | |||
Price To Earning | (18.43) X | |||
Price To Book | 1.42 X | |||
Price To Sales | 8.00 X | |||
Gross Profit | 5.87 M | |||
EBITDA | (39.41 M) | |||
Net Income | (53.53 M) | |||
Cash And Equivalents | 25.49 M | |||
Cash Per Share | 0.47 X | |||
Total Debt | 1.02 M | |||
Current Ratio | 0.68 X | |||
Book Value Per Share | 0.97 X | |||
Cash Flow From Operations | (24.8 M) | |||
Earnings Per Share | (1.72) X | |||
Beta | 0.39 | |||
Market Capitalization | 39.49 M | |||
Total Asset | 118.31 M | |||
Retained Earnings | (9 M) | |||
Working Capital | 41 M | |||
Current Asset | 44 M | |||
Current Liabilities | 3 M | |||
Z Score | 22.8 | |||
Net Asset | 118.31 M |
About Klaria Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Klaria Pharma Holding's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Klaria Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Klaria Pharma Holding based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Klaria Pharma Holding. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Complementary Tools for Klaria Stock analysis
When running Klaria Pharma's price analysis, check to measure Klaria Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Klaria Pharma is operating at the current time. Most of Klaria Pharma's value examination focuses on studying past and present price action to predict the probability of Klaria Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Klaria Pharma's price. Additionally, you may evaluate how the addition of Klaria Pharma to your portfolios can decrease your overall portfolio volatility.
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |